

Global Dual GLP-1R/GIPR Agonist Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

<https://marketpublishers.com/r/GAD9EFF15216EN.html>

Date: January 2026

Pages: 90

Price: US\$ 3,480.00 (Single User License)

ID: GAD9EFF15216EN

Abstracts

According to our (Global Info Research) latest study, the global Dual GLP-1R/GIPR Agonist market size was valued at US\$ 31519 million in 2025 and is forecast to a readjusted size of US\$ 65873 million by 2032 with a CAGR of 11.0% during review period.

In 2025, global Dual GLP-1R/GIPR Agonist production reached approximately 161.44 M Units, with an average global market price of around 190 USD per Unit.

A Dual GLP-1R/GIPR Agonist is a single therapeutic agent (usually a peptide) designed to activate both the GLP-1 receptor (GLP-1R) and the GIP receptor (GIPR). By stimulating these two incretin pathways together, it aims to improve metabolic control—typically by enhancing glucose-dependent insulin secretion, reducing glucagon when appropriate, slowing gastric emptying, and decreasing appetite/food intake—so it can support blood-glucose lowering and weight loss in conditions such as type 2 diabetes and obesity. To date, Tirzepatide is the only commercially available Dual GLP-1R/GIPR Agonist product in the world.

Dual GLP-1R/GIPR Agonists are reshaping the incretin field because they tackle a long-standing clinical and commercial pain point in metabolic care: achieving meaningful, sustained weight reduction and cardiometabolic improvement without forcing patients and providers into a tradeoff between efficacy, tolerability, and long-term adherence. By co-activating GLP-1 and GIP pathways in a single molecule, these therapies can deliver a broader metabolic effect than GLP-1 alone—supporting glucose control while driving appetite reduction and weight loss that can translate into improvements across obesity-linked comorbidities—while modern long-acting designs and carefully tuned receptor

balance aim to preserve potency with manageable gastrointestinal burden and simpler dosing routines. Industry momentum is being driven by unprecedented demand for effective obesity and diabetes treatments, rising recognition of obesity as a chronic disease with downstream health-system costs, strong payer and employer interest in outcomes that reduce long-term risk, and rapid advances in peptide engineering, formulation, and device delivery that make scalable, patient-friendly products feasible. The market potential remains substantial as dual agonists expand from specialist-driven use toward broader chronic-care adoption, diversify into new formulations and delivery formats, and compete through differentiation on tolerability, durability of effect, and real-world outcomes, positioning the category as a durable growth engine within biopharma's most strategically important therapeutic area.

The upstream raw materials for Dual GLP-1R/GIPR Agonist mainly include amino acids, condensation reagents, activators, resin carriers, etc. Typical raw material suppliers include Merck, Bachem, AAPPTec, Thermo Fisher, etc. The downstream applications are mainly in the treatment of obesity and diabetes.

The single-line production capacity of Dual GLP-1R/GIPR Agonist varies significantly depending on the drug molecule type, process complexity, equipment scale, and production mode. Industry gross margins typically range from 60% to 80%.

This report is a detailed and comprehensive analysis for global Dual GLP-1R/GIPR Agonist market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global Dual GLP-1R/GIPR Agonist market size and forecasts, in consumption value (\$ Million), sales quantity (K Units), and average selling prices (US\$/Unit), 2021-2032

Global Dual GLP-1R/GIPR Agonist market size and forecasts by region and country, in consumption value (\$ Million), sales quantity (K Units), and average selling prices (US\$/Unit), 2021-2032

Global Dual GLP-1R/GIPR Agonist market size and forecasts, by Type and by

Application, in consumption value (\$ Million), sales quantity (K Units), and average selling prices (US\$/Unit), 2021-2032

Global Dual GLP-1R/GIPR Agonist market shares of main players, shipments in revenue (\$ Million), sales quantity (K Units), and ASP (US\$/Unit), 2021-2026

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Dual GLP-1R/GIPR Agonist

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Dual GLP-1R/GIPR Agonist market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Eli Lilly, Roche, Viking Therapeutics, Asclepis Pharma, Jiangsu Hengrui Medicine, East China Pharmaceutical, Tonghua Dongbao Pharmaceutical, Lepu Medical Technology, Hansoh Pharma, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market Segmentation

Dual GLP-1R/GIPR Agonist market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type

Injection

Oral Administration

Others

Market segment by Receptor Agonist Properties

Balanced

Biased

Others

Market segment by Medicinal Efficacy

Long-acting

Short-acting

Market segment by Application

Diabetes

Obesity

Others

Major players covered

Eli Lilly

Roche

Viking Therapeutics

Asclepis Pharma

Jiangsu Hengrui Medicine

East China Pharmaceutical

Tonghua Dongbao Pharmaceutical

Lepu Medical Technology

Hansoh Pharma

Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Dual GLP-1R/GIPR Agonist product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Dual GLP-1R/GIPR Agonist, with price, sales quantity, revenue, and global market share of Dual GLP-1R/GIPR Agonist from 2021 to 2026.

Chapter 3, the Dual GLP-1R/GIPR Agonist competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Dual GLP-1R/GIPR Agonist breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.

Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026. and Dual GLP-1R/GIPR Agonist market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.

Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces

analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of Dual GLP-1R/GIPR Agonist.

Chapter 14 and 15, to describe Dual GLP-1R/GIPR Agonist sales channel, distributors, customers, research findings and conclusion.

I would like to order

Product name: Global Dual GLP-1R/GIPR Agonist Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Product link: <https://marketpublishers.com/r/GAD9EFF15216EN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GAD9EFF15216EN.html>